Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma

被引：0
|
作者：
Kim, G. P.
Oberg, A. L.
Foster, N. R.
Jaslowski, A.
Flynn, P. J.
Campbell, D.
Hedrick, E.
Gray, L.
Grothey, A.
Alberts, S.
机构：
[1] North Cent Canc Treatment Grp, Rochester, MN USA
[2] Sanofi Aventis, Bridgewater, NJ USA
[3] Genentech BioOncol, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4553
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
    Naohiro Okano
    Chigusa Morizane
    Shogo Nomura
    Hideaki Takahashi
    Hidetaka Tsumura
    Hironaga Satake
    Nobumasa Mizuno
    Kunihiro Tsuji
    Kazuhiko Shioji
    Akinori Asagi
    Kohichiroh Yasui
    Sho Kitagawa
    Tomomi Kashiwada
    Atsushi Ishiguro
    Masashi Kanai
    Makoto Ueno
    Takashi Ogura
    Satoshi Shimizu
    Kazutoshi Tobimatsu
    Masayo Motoya
    Koji Nakashima
    Masafumi Ikeda
    Takuji Okusaka
    Junji Furuse
    International Journal of Clinical Oncology, 2020, 25 : 1835 - 1843
  • [42] Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
    Okano, Naohiro
    Morizane, Chigusa
    Nomura, Shogo
    Takahashi, Hideaki
    Tsumura, Hidetaka
    Satake, Hironaga
    Mizuno, Nobumasa
    Tsuji, Kunihiro
    Shioji, Kazuhiko
    Asagi, Akinori
    Yasui, Kohichiroh
    Kitagawa, Sho
    Kashiwada, Tomomi
    Ishiguro, Atsushi
    Kanai, Masashi
    Ueno, Makoto
    Ogura, Takashi
    Shimizu, Satoshi
    Tobimatsu, Kazutoshi
    Motoya, Masayo
    Nakashima, Koji
    Ikeda, Masafumi
    Okusaka, Takuji
    Furuse, Junji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (10) : 1835 - 1843
  • [43] A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study
    Chiang, Nai-Jung
    Tsai, Kelvin K.
    Hsiao, Chin-Fu
    Yang, Shih-Hung
    Hsiao, Hui-Hua
    Shen, Wen-Chi
    Hsu, Chiun
    Lin, Yu-Lin
    Chen, Jen-Shi
    Shan, Yan-Shen
    Chen, Li-Tzong
    EUROPEAN JOURNAL OF CANCER, 2020, 124 : 123 - 130
  • [44] A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma
    Mudigonda, Tejaswi V.
    Wyman, Kenneth
    Spigel, David R.
    Dahlman, Kimberly B.
    Greco, F. Anthony
    Puzanov, Igor
    Kelley, Mark C.
    Hainsworth, John D.
    Sosman, Jeffrey A.
    Johnson, Douglas B.
    PIGMENT CELL & MELANOMA RESEARCH, 2016, 29 (01) : 101 - 103
  • [45] Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC).
    Balar, A. V.
    Milowsky, M. I.
    Apolo, A. B.
    Ostrovnaya, I.
    Iasonos, A.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Gallagher, D. J.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H. Ko
    Alan P. Venook
    Emily K. Bergsland
    R. Kate Kelley
    W. Michael Korn
    Elizabeth Dito
    Brian Schillinger
    Janet Scott
    Jimmy Hwang
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1051 - 1057
  • [47] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [48] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Phase II trial of oxaliplatin and gemcitabine in patients with malignant pleural or peritoneal mesothelioma
    Hare, E.
    Hesdorrfer, M. E.
    Leinwand, J.
    Batista, L.
    Taub, R. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] A phase II trial of weekly gemcitabine and bevacizumab in combination with abdominal radiation therapy in patients with localized pancreatic cancer
    Small, W., Jr.
    Mulcahy, M.
    Benson, A.
    Gold, S.
    Bredesen, R.
    Rademaker, F.
    Talamonti, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345